Would you consider administration of neoadjuvant anthracycline for cT2N1 ER+/PR+/HER2- patients given that this may be excessive for N1 disease, or do you wait until nodal status is confirmed on surgical pathology? 

Yes, I would consider anthracycline-based therapy in cT2N1M0 HR+/HER2-negative breast cancer. The ABC trial, the only large-scale trial testing anthracycline specifically in HER-negative cases, showed only a marginal benefit in disease-free survival (not quite statistically significant), and appeared to be more prominent in ER-negative or node+ (particularly N2 in HR+ cases) cases, although these subset analyses are not very reliable due to the small size with statistical trends only noted. (1) The most recent ASCO focused guidelines on optimal adjuvant chemotherapy recommend anthracycline-based therapy for higher risk patients who can tolerate treatment and offers non-anthracycline options otherwise. (2) The Oxford overview analysis focusi...